Claims

AR simulators for tumor localization and intraoperative guidance were tested on small patient subsets, limiting generalizability

Claim · All claims
Evidence · 1 study · review r3 · q3
Currency · newest study 2025 · not yet checked against its sources · not reviewed by a person · recheck by 2028: tool and model accuracy changes quickly

Subclaims

Reading the evidence codes

q is the design tier, i the impact, n the sample, and the kind with its r the rigour judged within that kind: what each code means.

This claim: no standardized effect is recorded in observations/ for it yet, so no benchmark reading is possible.

q3 i? Most AR simulation studies in neuro-oncology were case series with small samples, restricting the generalizability of reported utility and effectiveness. → Menna Grazia 2025

Evidence

Menna Grazia 2025

Menna Grazia, Riva Dora, Marino Salvatore, Garber Jocelyn, Gerritsen Jasper Kees Wim, Mattogno Pier Paolo, Young Jacob Stewart, Olivi Alessandro, Doglietto Francesco, Berger Mitchel Stuart, Della Pepa Giuseppe Maria. (2025). Simulation tools in neuro-oncological surgery: a scoping review of perioperative and training applications. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-04972-8

q3 · i? · review · r3

The review's synthesis of AR studies found that "a notable limitation across most studies was that the AR simulators were tested on a small subset of neurosurgical patients", which the authors state restricts generalizability.

"Nonetheless, a notable limitation across most studies was that the AR simulators were tested on a small subset of neurosurgical patients, which restricts the generalizability of their reported utility and effectiveness [6, 8, 10, 15, 19, 28, 29, 50, 60, 66, 67, 69]."

Discussion

Page metadata
Field Value
status review
generated by process:wiki-ingest on 2026-10-31
trust unverified — no one has confirmed this page's content

Frontmatter is the page's machine-readable record — see the Schema & Guide.